Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0SOUGE
ADC Name
IL2-CCR4 IT
Synonyms
IL2-CCR4-IT
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Cutaneous T-cell lymphoma [ICD11:2B00]
Investigative
Antibody Name
DT390
  Antibody Info 
Antigen Name
C-C chemokine receptor type 4 (CCR4)
  Antigen Info 
Payload Name
IL2 fusion toxin
  Payload Info 
Therapeutic Target
Interleukin-2 receptor subunit alpha (IL2RA)
  Target Info 
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
6.3
pM
HUT102/6TG cells
Cutaneous T cell lymphoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 6.30 pM Positive CCR4 expression (CCR4 +++/++)
Method Description
In vitro efficacy comparison of the CCR4 IT vs IL2 fusion toxin to human CCR4+ CTCL Hut102/6TG using luminescent cell viability assay.
In Vitro Model Cutaneous T cell lymphoma HUT102/6TG cells Homo sapiens
References
Ref 1 Bispecific human IL2-CCR4 immunotoxin targets human cutaneous T-cell lymphoma. Mol Oncol. 2020 May;14(5):991-1000. doi: 10.1002/1878-0261.12653. Epub 2020 Mar 13.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.